Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury

Journal of Hypertension

Volumn 15, Issue 10, 1997, Pages 1181-1185

  Bakris, George L ^a   Griffin, Karen A ^b,c   Picken, Maria M ^b,c   Bidani, Anil K ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium antagonist; Glomerulosclerosis; Hypertension; Proteinuria

Indexed keywords

AMLODIPINE; BENAZEPRIL; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; GLOMERULOSCLEROSIS; INULIN CLEARANCE; KIDNEY DISEASE; MALE; MORPHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0030883135     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715100-00017     Document Type: Article

References (26)

1. Perna A, Remuzzi G: Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996, 27:34-41.
2. Mimran A, Insua A, Ribstein J, Bringer J, Monnier L: Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988, 11:850-853.
3. Demarie B, Bakris GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990, 113:987-988.
4. Bakris GL, Mehler P, Schrier R: Hypertension and diabetes. In Diseases of the Kidney. Sixth Edition. Edited by Schrier RW, Gottschalk CW. Boston: Little Brown & Company; 1996:1281-1328.
5. Maki DD, Ma JZ, Louis TA, Kasiske BL: Effects of antihypertensive agents on the kidney. Arch Intern Med 1995, 155:1073-1082.
6. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995, 96:793-800.
7. Gaber L, Walton C, Brown S, Bakris GL: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994, 46:161-169.
8. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641-1650.
9. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Calcium antagonists and progression of diabetic nephropathy in African-Americans. Hypertension 1997, 29:744-750.
10. Abbott K, Smith AC, Bakris GL: Effects of dihydropyridine calcium antagonists on albuminuria in diabetic subjects. J Clin Pharmacol 1996, 36:274-279.
11. Bakris GL, Smith AC: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996, 125:201-203.
12. Munter K, Hergenroder S, Jochims K, Kirchengast M: Individual and combined effects of verapamil or transolapril on glomerular morphology and function in the stroke prone rat. J Am Soc Nephrol 1996, 7:681-686.
13. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15.
14. Smith AC, Bakris GL: Differential effects of calcium channel blockers on albuminuria and glomerular permeablity in NIDDM subjects with nephropathy: pilot results of a two year study [abstract]. J Am Soc Nephrol 1996, 7:1364.
15. Griffin KA, Picken M, Bidani AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994, 46:1010-1018.
16. Kilaru PK, Bakris GL: ACE inhibition or calcium channel blockade: renal implications of combination therapy versus a single agent. J Cardiovasc Pharmacol 1996, 28 (suppl 2):S34-S44.
17. Picken M, Griffin K, Bakris GL, Bidani A: Differences in the antihypertensive and glomeruloprotective efficacies of calcium channel blockers in a remnant kidney model [abstract]. J Am Soc Nephrol 1996, 7:1586.
18. Bakris GL, White D: Effects of an ACE inhibitor combined with calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997, 11:35-38.
19. Lash JP, Bakris GL: Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant 1995, 10 (suppl 9):56-62.
20. Bakris GL: An approach to the hypertensive diabetic patient: emphasis on renal preservation. In Calcium Antagonists in Clinical Medicine. Edited by Epstein M. Philadelphia: Hanley and Belfus; 1992:326-352.
21. Brown S, Walton C, Crawford P, Bakris GL: Comparative renal hemodynamic effects of an ACE inhibitor or calcium antagonist on progression of diabetic nephropathy in the dog. Kidney Int 1993, 43:1210-1218.
22. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996, 27:245-250.
23. National High Blood Pressure Education Program Working Group: 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996, 156:1938-1947.
24. Lazarus JM, Bourgoignie JJ, Buckalew VM, Green E, Levey AS, Milas NC, et al.: Achievement and safety of a low blood pressure goal in chronic renal disease: the modification of diet on renal disease study group. Hypertension 1997, 29:641-650.
25. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987, 252:F1003-F1010.
26. Bidani AK, Griffin AK, Picken M, Lansky DM: Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 1993, 265:F391-F398.